Shortening treatment for tuberculosis--to basics.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

34 citing papers in PubMed, 2 syntheses or guidelines pooled it.

1. Effect of Xpert MTB/RIF on clinical outcomes in routine care settings: individual patient data meta-analysis.The Lancet. Global health · 2019
   Pooled it
2. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2016
   Guideline
3. Efficacy and safety of a 4-month quabodepistat, delamanid, and bedaquiline regimen for drug-susceptible pulmonary tuberculosis: a multicentre, open-label, randomised, proof-of-concept, non-inferiority, phase 2b/c trial.The Lancet. Infectious diseases · 2026
   Trial
4. An HLA-E-targeted TCR bispecific molecule redirects T cell immunity against Mycobacterium tuberculosis.Proceedings of the National Academy of Sciences of the United States of America · 2024
   Article
5. TZD-Based Hybrid Molecules Act as Dual Anti-International journal of molecular sciences · 2023
   Article
6. Pediatric Tuberculosis Management: A Global Challenge or Breakthrough?Children (Basel, Switzerland) · 2022
   Review
7. Chemical and Pharmacological Properties of Decoquinate: A Review of Its Pharmaceutical Potential and Future Perspectives.Pharmaceutics · 2022
   Review
8. Bacterial growth dynamics and pharmacokinetic-pharmacodynamic relationships of rifampicin and bedaquiline in BALB/c mice.British journal of pharmacology · 2022
   Article
9. Pharmacological and genetic activation of cAMP synthesis disrupts cholesterol utilization in Mycobacterium tuberculosis.PLoS pathogens · 2022
   Article
10. Elucidating the Antimycobacterial Mechanism of Action of Decoquinate Derivative RMB041 Using Metabolomics.Antibiotics (Basel, Switzerland) · 2021
    Article
11. Quantitative 18F-FDG PET-CT scan characteristics correlate with tuberculosis treatment response.EJNMMI research · 2020
    Article
12. Advantages and Challenges of Tailored Regimens for Drug-Resistant Tuberculosis: A StopTB Italia Look into the Future.Infection and drug resistance · 2020
    Review
13. Viable Mycobacterium tuberculosis in sputum after pulmonary tuberculosis cure.BMC infectious diseases · 2019
    Article
14. AnFrontiers in pharmacology · 2019
    Article
15. Differentially Detectable Mycobacterium tuberculosis Cells in Sputum from Treatment-Naive Subjects in Haiti and Their Proportionate Increase after Initiation of Treatment.mBio · 2018
    Article
16. Drug permeation and metabolism in Mycobacterium tuberculosis: Prioritising local exposure as essential criterion in new TB drug development.IUBMB life · 2018
    Review
17. Preclinical tools for the evaluation of tuberculosis treatment regimens for children.The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease · 2018
    Review
18. Novel Antitubercular 6-Dialkylaminopyrimidine Carboxamides from Phenotypic Whole-Cell High Throughput Screening of a SoftFocus Library: Structure-Activity Relationship and Target Identification Studies.Journal of medicinal chemistry · 2017
    Article
19. A Review of Moxifloxacin for the Treatment of Drug-Susceptible Tuberculosis.Journal of clinical pharmacology · 2017
    Review
20. Preclinical Efficacy Testing of New Drug Candidates.Microbiology spectrum · 2017
    Review

Corrections and comments

• Comment on
  Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis.2014
• Comment on
  A four-month gatifloxacin-containing regimen for treating tuberculosis.2014
• Comment on
  High-dose rifapentine with moxifloxacin for pulmonary tuberculosis.2014

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as